Literature DB >> 30706376

Natural History and Treatment Trends in Pancreatic Cancer Subtypes.

Courtney J Pokrzywa1, Daniel E Abbott2, Kristina A Matkowskyj3, Sean M Ronnekleiv-Kelly2, Emily R Winslow2, Sharon M Weber2, Alexander V Fisher4.   

Abstract

BACKGROUND: While pancreatic ductal adenocarcinoma is the most common form of pancreatic cancer, many other histologic forms of pancreatic cancer are also recognized. These histologic variants portray unique characteristics in terms of patient demographics, tumor behavior, survival, and responsiveness to treatments.
MATERIALS AND METHODS: Patients who underwent surgical resection of the pancreas for non-metastatic, invasive pancreatic cancer between 2004 and 2014 were selected from the National Cancer Data Base and categorized by histologic variant according to WHO classification guidelines. Patient demographics, tumor variables, treatment characteristics, and survival were compared between histologic groups and subgroups.
RESULTS: A total of 57,804 patients met inclusion and exclusion criteria and were grouped into eight major histologic categories. Survival analysis by the histologic group showed median overall survival of 20.2 months for ductal adenocarcinoma, 20.5 months for squamous cell carcinoma, 26.8 months for mixed acinar-neuroendocrine carcinomas, 52.6 months for cystic mucinous neoplasms with an associated invasive carcinoma, 67.5 months for acinar cell carcinoma, and 69.3 months for mesenchymal tumors. Median survival was not reached for neuroendocrine tumors and solid-pseudopapillary neoplasms, with 5-year overall survival rates of 84% and 97% respectively.
CONCLUSIONS: Rare subtypes of pancreatic cancer present unique clinicopathologic characteristics and display distinct tumor biologies. This study presents data on demographic, prognostic, treatment, and survival outcomes between rare forms of pancreatic neoplasms in order to aid understanding of the natural history and behavior of these neoplasms, with the hope of serving as a reference in clinical decision-making and ability to provide accurate prognostic information to patients.

Entities:  

Keywords:  Mucinous neoplasms; Neuroendocrine tumors; Pancreatic adenocarcinoma; Pancreatic cancer subtypes

Mesh:

Year:  2019        PMID: 30706376     DOI: 10.1007/s11605-019-04113-3

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  69 in total

1.  Long term survival after pancreatic resection for pancreatic adenocarcinoma.

Authors:  N A Ahmad; J D Lewis; G G Ginsberg; D G Haller; J B Morris; N N Williams; E F Rosato; M L Kochman
Journal:  Am J Gastroenterol       Date:  2001-09       Impact factor: 10.864

2.  Surgical treatment of pancreatic adenocarcinoma; actual survival and prognostic factors in 343 patients.

Authors:  K F D Kuhlmann; S M M de Castro; J G Wesseling; F J W ten Kate; G J A Offerhaus; O R C Busch; T M van Gulik; H Obertop; D J Gouma
Journal:  Eur J Cancer       Date:  2004-03       Impact factor: 9.162

Review 3.  Squamous cell carcinoma of the pancreas.

Authors:  Hilary A Brown; Jorge Dotto; Marie Robert; Ronald R Salem
Journal:  J Clin Gastroenterol       Date:  2005 Nov-Dec       Impact factor: 3.062

4.  Outcomes following resection of invasive and noninvasive intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Keita Wada; Richard A Kozarek; L William Traverso
Journal:  Am J Surg       Date:  2005-05       Impact factor: 2.565

5.  Pancreatic mucinous cystic neoplasm defined by ovarian stroma: demographics, clinical features, and prevalence of cancer.

Authors:  Raghuram P Reddy; Thomas C Smyrk; Mauricio Zapiach; Michael J Levy; Randall K Pearson; Jonathan E Clain; Michael B Farnell; Michael G Sarr; Suresh T Chari
Journal:  Clin Gastroenterol Hepatol       Date:  2004-11       Impact factor: 11.382

6.  Differences in survival by histologic type of pancreatic cancer.

Authors:  Megan Dann Fesinmeyer; Melissa A Austin; Christopher I Li; Anneclaire J De Roos; Deborah J Bowen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-07       Impact factor: 4.254

7.  Mixed acinar-endocrine carcinoma of the pancreas. A clinicopathological study and comparison with acinar-cell carcinoma.

Authors:  Nobuyuki Ohike; Markus Kosmahl; Günter Klöppel
Journal:  Virchows Arch       Date:  2004-07-29       Impact factor: 4.064

8.  Intraductal papillary mucinous neoplasms of the pancreas: an analysis of clinicopathologic features and outcome.

Authors:  Michael D'Angelica; Murray F Brennan; Arief A Suriawinata; David Klimstra; Kevin C Conlon
Journal:  Ann Surg       Date:  2004-03       Impact factor: 12.969

9.  Prognostic factors in resected pancreatic adenocarcinoma: analysis of actual 5-year survivors.

Authors:  Sean P Cleary; Robert Gryfe; Maha Guindi; Paul Greig; Lloyd Smith; Robert Mackenzie; Steven Strasberg; Sherif Hanna; Bryce Taylor; Bernard Langer; Steven Gallinger
Journal:  J Am Coll Surg       Date:  2004-05       Impact factor: 6.113

10.  Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma.

Authors:  M Wagner; C Redaelli; M Lietz; C A Seiler; H Friess; M W Büchler
Journal:  Br J Surg       Date:  2004-05       Impact factor: 6.939

View more
  9 in total

1.  Mixed neuroendocrine nonneuroendocrine neoplasms of the pancreas: a case report and literature review of pancreatic mixed neuroendocrine nonneuroendocrine neoplasm.

Authors:  Fei Wang; Xin Lou; Yi Qin; Xiaowu Xu; Xianjun Yu; Dan Huang; Shunrong Ji
Journal:  Gland Surg       Date:  2021-12

2.  Curcumol inhibits the growth of xenograft-tumors in mice and the biological activities of pancreatic cancer cells by regulating the miR-21-5p/SMAD7 axis.

Authors:  Songlin Fang; Lezeng Wang; Chunmei Luo; Hang Yi; Xiangrui Wang; Bo Ning
Journal:  Cell Cycle       Date:  2022-03-06       Impact factor: 5.173

3.  Tanshinone IIA inhibits glucose metabolism leading to apoptosis in cervical cancer.

Authors:  Zhigang Liu; Wenhe Zhu; Xiangyu Kong; Xi Chen; Xinyi Sun; Wei Zhang; Ruowen Zhang
Journal:  Oncol Rep       Date:  2019-08-27       Impact factor: 3.906

4.  Nomogram Predicts Risk and Prognostic Factors for Bone Metastasis of Pancreatic Cancer: A Population-Based Analysis.

Authors:  Wei Zhang; Lichen Ji; Xijun Wang; Senbo Zhu; Junchao Luo; Yin Zhang; Yu Tong; Fabo Feng; Yao Kang; Qing Bi
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-09       Impact factor: 5.555

5.  Spleen Preservation in Laparoscopic Distal Pancreatectomy for Solitary Pseudopapillary Tumors Is Oncologic Safe.

Authors:  Seog Ki Min
Journal:  J Minim Invasive Surg       Date:  2019-03-15

6.  Carboxypeptidase A1 (CPA1) Immunohistochemistry Is Highly Sensitive and Specific for Acinar Cell Carcinoma (ACC) of the Pancreas.

Authors:  Ria Uhlig; Hendrina Contreras; Sören Weidemann; Natalia Gorbokon; Anne Menz; Franziska Büscheck; Andreas M Luebke; Martina Kluth; Claudia Hube-Magg; Andrea Hinsch; Doris Höflmayer; Christoph Fraune; Katharina Möller; Christian Bernreuther; Patrick Lebok; Guido Sauter; Waldemar Wilczak; Jakob Izbicki; Daniel Perez; Jörg Schrader; Stefan Steurer; Eike Burandt; Rainer Krech; David Dum; Till Krech; Andreas Marx; Ronald Simon; Sarah Minner; Frank Jacobsen; Till S Clauditz
Journal:  Am J Surg Pathol       Date:  2022-01-01       Impact factor: 6.394

Review 7.  Pancreatic Cancer and the Obesity Epidemic: A Narrative Review.

Authors:  Devyani S Poman; Lakshya Motwani; Nailah Asif; Apurva Patel; Deepanjali Vedantam
Journal:  Cureus       Date:  2022-07-08

8.  Meta-analysis of fish consumption and risk of pancreatic cancer in 13 prospective studies with 1.8 million participants.

Authors:  Wei Jiang; Min Wang; Hai-Zhong Jiang; Guo-Chong Chen; Yong-Fei Hua
Journal:  PLoS One       Date:  2019-09-06       Impact factor: 3.240

9.  The eighth version of American Joint Committee on Cancer nodal classification for high grade pancreatic neuroendocrine tumor should be generalized for the whole population with this disease.

Authors:  Mu-Xing Li; Hang-Yan Wang; Chun-Hui Yuan; Chao-Lai Ma; Bin Jiang; Lei Li; Li Zhang; Hong Zhao; Jian-Qiang Cai; Dian-Rong Xiu
Journal:  Medicine (Baltimore)       Date:  2020-09-11       Impact factor: 1.817

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.